Tech and kabonk: the issue is the FDA asked for CD16.. if CD16 has any overlap with CD12 (and it should), how are you going to justify running a study with a placebo arm, where people can get just SOC, and have Open Label Extension for the drug, where you're guaranteed to get it?

Who would sign up for the 50% chance to get nothing, being severe or critical, with nothing else working?

Something doesn't compute.. assuming we'll know more in a few hours.